Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer
BackgroundEarly diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers for lung cancer detection. Copper transporter 1 (COPT1) is abnormally expressed in several cancers including lung ca...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455095/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211796069122048 |
|---|---|
| author | Xiaobin Cao Xiaobin Cao Jing Li Siyu Liu Siyu Liu Aichen Liu Lulu Zhang Fengqi Chen Yutong Li Yutong Li Hanke Ma Wenke Sun Songyun Ouyang Liping Dai Jingjing Liu |
| author_facet | Xiaobin Cao Xiaobin Cao Jing Li Siyu Liu Siyu Liu Aichen Liu Lulu Zhang Fengqi Chen Yutong Li Yutong Li Hanke Ma Wenke Sun Songyun Ouyang Liping Dai Jingjing Liu |
| author_sort | Xiaobin Cao |
| collection | DOAJ |
| description | BackgroundEarly diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers for lung cancer detection. Copper transporter 1 (COPT1) is abnormally expressed in several cancers including lung cancer. The purpose of this study is to explore the significance of anti-COPT1 autoantibodies in the clinical diagnosis of non-small cell lung cancer (NSCLC).MethodsThe expression level of COPT1 in NSCLC and normal tissues was analyzed based on TCGA and the Human Protein Atlas (HPA) database. Through enzyme-linked immunosorbent assay (ELISA), the expression levels of anti-COPT1 autoantibodies in plasma samples from normal controls (NC), patients with benign pulmonary nodules (BPN), and patients with NSCLC were detected in the discovery (89 NC and 89 NSCLC) and verification (321 NC, 321 BPN and 321 NSCLC) groups. The ELISA results were verified by western blotting and indirect immunofluorescence experiments.ResultsBased on HPA and TCGA databases, the mRNA and protein levels of COPT1 were higher in NSCLC tissues than in normal tissues. The levels of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies were significantly higher in patients with NSCLC (P<0.05). Anti-COPT1-IgG and anti-COPT1-IgM could discriminate NSCLC from NC with area under the curve (AUC) values of 0.733 (95% CI: 0.694-0.771) and 0.679 (95% CI: 0.638-0.720), respectively. Additionally, the combination of anti-COPT1-IgG, anti-COPT1-IgM, and carcinoembryonic antigen (CEA) could enhance the efficacy of NSCLC diagnosis from BPN with increased AUC values.ConclusionsOur study indicated the potential significance of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies as novel biomarkers for the detection of NSCLC. Furthermore, the combination of anti-COPT1-IgG and anti-COPT1-IgM improved the diagnostic value. |
| format | Article |
| id | doaj-art-ca4ea71410fc48429be4c30b9066d2be |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-ca4ea71410fc48429be4c30b9066d2be2025-08-20T02:09:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.14550951455095Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancerXiaobin Cao0Xiaobin Cao1Jing Li2Siyu Liu3Siyu Liu4Aichen Liu5Lulu Zhang6Fengqi Chen7Yutong Li8Yutong Li9Hanke Ma10Wenke Sun11Songyun Ouyang12Liping Dai13Jingjing Liu14Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaDepartment of Respiratory and Sleep Medicine in the First Affiliated hospital, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, ChinaBackgroundEarly diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers for lung cancer detection. Copper transporter 1 (COPT1) is abnormally expressed in several cancers including lung cancer. The purpose of this study is to explore the significance of anti-COPT1 autoantibodies in the clinical diagnosis of non-small cell lung cancer (NSCLC).MethodsThe expression level of COPT1 in NSCLC and normal tissues was analyzed based on TCGA and the Human Protein Atlas (HPA) database. Through enzyme-linked immunosorbent assay (ELISA), the expression levels of anti-COPT1 autoantibodies in plasma samples from normal controls (NC), patients with benign pulmonary nodules (BPN), and patients with NSCLC were detected in the discovery (89 NC and 89 NSCLC) and verification (321 NC, 321 BPN and 321 NSCLC) groups. The ELISA results were verified by western blotting and indirect immunofluorescence experiments.ResultsBased on HPA and TCGA databases, the mRNA and protein levels of COPT1 were higher in NSCLC tissues than in normal tissues. The levels of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies were significantly higher in patients with NSCLC (P<0.05). Anti-COPT1-IgG and anti-COPT1-IgM could discriminate NSCLC from NC with area under the curve (AUC) values of 0.733 (95% CI: 0.694-0.771) and 0.679 (95% CI: 0.638-0.720), respectively. Additionally, the combination of anti-COPT1-IgG, anti-COPT1-IgM, and carcinoembryonic antigen (CEA) could enhance the efficacy of NSCLC diagnosis from BPN with increased AUC values.ConclusionsOur study indicated the potential significance of anti-COPT1-IgG and anti-COPT1-IgM autoantibodies as novel biomarkers for the detection of NSCLC. Furthermore, the combination of anti-COPT1-IgG and anti-COPT1-IgM improved the diagnostic value.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455095/fullCOPT1autoantibodynon-small cell lung cancerbiomarkersIgGIgM |
| spellingShingle | Xiaobin Cao Xiaobin Cao Jing Li Siyu Liu Siyu Liu Aichen Liu Lulu Zhang Fengqi Chen Yutong Li Yutong Li Hanke Ma Wenke Sun Songyun Ouyang Liping Dai Jingjing Liu Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer Frontiers in Immunology COPT1 autoantibody non-small cell lung cancer biomarkers IgG IgM |
| title | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer |
| title_full | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer |
| title_fullStr | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer |
| title_full_unstemmed | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer |
| title_short | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer |
| title_sort | plasma igg and igm autoantibodies to copt1 as potential biomarkers for detection of non small cell lung cancer |
| topic | COPT1 autoantibody non-small cell lung cancer biomarkers IgG IgM |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1455095/full |
| work_keys_str_mv | AT xiaobincao plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT xiaobincao plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT jingli plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT siyuliu plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT siyuliu plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT aichenliu plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT luluzhang plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT fengqichen plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT yutongli plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT yutongli plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT hankema plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT wenkesun plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT songyunouyang plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT lipingdai plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer AT jingjingliu plasmaiggandigmautoantibodiestocopt1aspotentialbiomarkersfordetectionofnonsmallcelllungcancer |